Alentis Therapeutics

Alentis Therapeutics is a clinical stage biotechnology company focused on developing pioneering treatments for Claudin1-positive tumors and organ fibrosis. The company's innovative approach targets CLDN1, an unexploited key player in tumor pathology and fibrotic diseases across multiple organs. Alentis is uniquely positioned as the sole developer of potential treatments for solid cancers and fibrosis that target CLDN1. Their portfolio includes anti-CLDN1 monoclonal antibodies, particularly ALE.C04, the first potential treatment to target CLDN1 in solid tumors. Additionally, their pipeline features therapies, such as ALE.F02, designed to reverse advanced organ fibrosis, currently in Phase 1 clinical trials for the treatment of fibrotic disease in the kidney, lung, and liver. Established in 2019 based on groundbreaking research at the University of Strasbourg and French National Institute of Health (Inserm), Alentis is headquartered in Basel, Switzerland, with a subsidiary for R&D in Strasbourg, France. The company's recent grant investment on 28 April 2023 was received from Innosuisse. For more information, visit Alentis Therapeutics or email [email protected].